Signature Estate & Investment Advisors LLC Invests $343,000 in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Signature Estate & Investment Advisors LLC acquired a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 658 shares of the medical equipment provider’s stock, valued at approximately $343,000.

Several other institutional investors have also added to or reduced their stakes in the company. Proficio Capital Partners LLC raised its holdings in shares of Intuitive Surgical by 89,098.8% during the 4th quarter. Proficio Capital Partners LLC now owns 949,967 shares of the medical equipment provider’s stock worth $495,845,000 after buying an additional 948,902 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Intuitive Surgical during the fourth quarter worth about $313,769,000. Wilmington Savings Fund Society FSB lifted its holdings in shares of Intuitive Surgical by 15,322.2% in the third quarter. Wilmington Savings Fund Society FSB now owns 555,661 shares of the medical equipment provider’s stock worth $272,980,000 after acquiring an additional 552,058 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Intuitive Surgical by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 32,212,196 shares of the medical equipment provider’s stock valued at $16,813,478,000 after purchasing an additional 360,591 shares in the last quarter. Finally, GQG Partners LLC grew its holdings in shares of Intuitive Surgical by 42.5% during the 4th quarter. GQG Partners LLC now owns 1,145,300 shares of the medical equipment provider’s stock valued at $597,801,000 after purchasing an additional 341,812 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Intuitive Surgical

In related news, EVP Robert Desantis sold 11,545 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $499.22, for a total value of $5,763,494.90. Following the completion of the sale, the executive vice president now directly owns 5,224 shares of the company’s stock, valued at $2,607,925.28. The trade was a 68.85 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Jamie Samath sold 269 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $590.00, for a total value of $158,710.00. Following the completion of the sale, the chief financial officer now directly owns 3,282 shares of the company’s stock, valued at $1,936,380. This trade represents a 7.58 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,754 shares of company stock worth $17,691,621 in the last quarter. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of ISRG opened at $509.03 on Thursday. The firm has a market cap of $181.31 billion, a PE ratio of 79.41, a price-to-earnings-growth ratio of 5.85 and a beta of 1.43. Intuitive Surgical, Inc. has a 52-week low of $364.17 and a 52-week high of $616.00. The business’s 50 day moving average price is $559.82 and its two-hundred day moving average price is $532.42.

Wall Street Analyst Weigh In

A number of analysts have weighed in on ISRG shares. UBS Group raised their target price on shares of Intuitive Surgical from $500.00 to $560.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Citigroup raised their price objective on Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a report on Friday, January 24th. Raymond James upped their target price on Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a report on Friday, January 24th. Barclays lifted their price target on Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. Finally, JPMorgan Chase & Co. upped their price objective on Intuitive Surgical from $575.00 to $675.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and a consensus price target of $611.86.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.